This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Olympus Biotech International Ltd And BonAlive Biomaterials Ltd Announce Distribution Agreement

BonAlive Biomaterials Ltd is an emerging leader in the field of implantable medical devices for bone regeneration. The focus is to provide world-leading biomaterial solutions for the treatment of chronically infected bone. BonAlive ® products are available in Europe, Middle East, Asia-Pacific, Africa, Brazil and the USA through a professional distributor network. The clinical use of BonAlive ® is supported by a twenty year research history including several randomized prospective trials in the field of spine, benign bone tumor and trauma surgery. More than fifty peer reviewed articles have been published about BonAlive ®.

About Olympus Biotech International Limited

Olympus Biotech was established in December, 2010 as a wholly owned company of Olympus Corporation. The vision of Olympus Biotech is to improve the patient Quality of Life by developing and distributing Regenerative Medicine that stimulates the intrinsic healing capacity in the living body. Olympus Biotech provides minimally-invasive regenerative therapies for bone and soft tissue including growth factors, scaffolds and cell harvesting technologies as well as tools for access, placement and delivery.

For questions or additional information, please contact:

Olympus Biotech International Limited Dirk Dembski Vice President Marketing and Business Development Olympus Biotech International   Mobile +49-172-2492700 dirk.dembski@olympusbiotech.com BonAlive Biomaterials Ltd: Fredrik Ollila, PhD Chief Executive Officer BonAlive Biomaterials Ltd Mobile +358(0)400-931-209 Fax +358(0)421-917-744-00 fredrik.ollila@bonalive.com

SOURCE BonAlive Biomaterials Ltd

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,582.13 -16.07 -0.09%
S&P 500 2,099.06 +1.02 0.05%
NASDAQ 5,115.3750 -0.0070 -0.00%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs